The content on this site is intended for healthcare professionals only
Prof Tanya Wildes speaks to ecancer at the SIOG 2019 meeting in Geneva about how polypharmacy affects mobility in older patients.
Firstly, Prof Wildes explored some of the current mobility tests and their conclusions in geriatric oncology assessments.
She then looked at how some of the conclusions (e.g. an increase in falls) also were the same risks associated of certain medications, and that this may impact mobility.
Prof Wildes concluded that there needs to be an accurate representation of the patient's medication so that mobility can be reviewed and understood in the context of their polypharmacy regimen.
More information on the Cancer and Ageing Research Group mentioned in the video can be found here.
This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Fracture risk increases following cancer therapies for advanced prostate cancer
Gaza's cancer patients: Navigating the dual struggle of illness and war
Cancer in emergencies: What can we do better to protect the most vulnerable?
Patient expectations and shared decision making in aRCC
Grand Rounds: Improving quality of patient-centred care
Do patients and doctors treatment aspirations align? KCCure survey – part A
The enhancing oncology model and other value-based propositions
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
